研究单位：[1]Tianjin Medical University Cancer Institute and Hospital[2]TianJin Medical University Cancer Institute and Hospitall[3]The First Affiliated Hospital of Zhengzhou University[4]The First Affiliated Hospital of Hainan Medical University[5]Shandong Cancer Hospital and Institute[6]First Affiliated Hospital of Kunming Medical University[7]Chongqing University Cancer Hospital[8]Tangshan People's Hospital[9]Taizhou Hospital[10]Tianjin medical university cancer institute and hospital,Tianjin,China
研究目的：
Phase II multicenter prospective study on the safety of eliminating surgery for triple negative or HER2 positive breast cancer patients with clinical response to neoadjuvant radiotherapy and neoadjuvant chemotherapy.
